Breast and Cervical Cancer Early Detection Program to Expand

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 12
Volume 5
Issue 12

WASHINGTON--For the first time since its inception in 1991, funds from the Breast and Cervical Cancer Early Detection Program will flow to all 50 states in fiscal 1997, the Department of Health and Human Services announced.

WASHINGTON--For the first time since its inception in 1991, fundsfrom the Breast and Cervical Cancer Early Detection Program willflow to all 50 states in fiscal 1997, the Department of Healthand Human Services announced.

In addition to the 50 states and the District of Columbia, fundsfor the education and screening effort will go to three territories--theNorthern Mariana Islands, the Republic of Palau, and the VirginIslands--and 13 American Indian and Alaska Native organizations.

The CDC program serves low-income and minority women. From itsbeginning through May 1996, it has provided 457,600 mammogramsto women--2,495 of whom were diagnosed with breast cancer--and612,000 Pap tests, which found cervical intraepithelial neoplasiain 19,166 women and invasive cancer in 239.

Related Videos
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Despite the addition of a TIGIT inhibitor to a checkpoint inhibitor resulting in high levels of safety, there is no future for that combination alone, according to Ritu Salani, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Related Content